MedCap Q2 2025: EBITA beat, thesis playing out as expected - Redeye

Redeye provides its initial take on MedCap’s Q2 2025 report, which roughly matched our top-line projection and beat our adjusted EBITA estimate. As expected, softening comparables and continued growth resulted in MedCap returning to y/y profit expansion this quarter. We expect the company to sustain its momentum in coming quarters.

Länk till analysen i sin helhet: https://www.redeye.se/research/1120410/medcap-q2-2025-ebita-beat-thesis-playing-out-as-expected?utm_source=finwire&utm_medium=RSS